FCGR1A and prostate carcinoma: We previously reported this treatment has minimal toxicities, no changes in quality of life and was able to delay the initiation of conventional salvage therapy for at least 12 months in 8 out of 15 participants.19 Our data show that hematologic changes were relatively short-lived with the exception of monocyte expression of CD64, which can potentially be viewed as a marker of prostate cancer progression.